Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2016 Sep 9;6:32804. doi: 10.1038/srep32804

CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis

Xiaoyan Xin 1,*, Xianqin Zeng 2,*, Huajian Gu 3,*, Min Li 1,4, Huaming Tan 5, Zhishan Jin 1, Teng Hua 1, Rui Shi 1, Hongbo Wang 1,a
PMCID: PMC5016850  PMID: 27608940

Abstract

CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) plays an important role in tumor progression and a number of studies have suggested that it is an indicator of tumor prognosis. This current meta-analysis systematically reevaluated the predictive potential of CD147/EMMPRIN in various cancers. We searched PubMed and Embase databases to screen the literature. Fixed-effect and random-effect meta-analytical techniques were used to correlate CD147 expression with outcome measures. A total of 53 studies that included 68 datasets were eligible for inclusion in the final analysis. We found a significant association between CD147/EMMPRIN overexpression and adverse tumor outcomes, such as overall survival, disease-specific survival, progression-free survival, metastasis-free survival or recurrence-free survival, irrespective of the model analysis. In addition, CD147/EMMPRIN overexpression predicted a high risk for chemotherapy drugs resistance. CD147/EMMPRIN is a central player in tumor progression and predicts a poor prognosis, including in patients who have received chemo-radiotherapy. Our results provide the evidence that CD147/EMMPRIN could be a potential therapeutic target for cancers.

The incidence of various cancers has been increasing and cancer is the most deadly disease threatening human life. One of the main causes of deaths is the inherent metastatic property of malignant tumors. This poses great difficulty in developing clinical therapeutics. The multi-linked pathological processes of tumor metastasis include: basement membrane degradation, matrix permeability, forward movement of tumor cells including secondary growth, and interaction between tumor cells and host stromal cells. CD147/EMMPRIN, also known as basigin or M6 antigen, has been shown to play an important role in tumor metastasis by stimulating tumor stromal cells to produce matrix metalloproteinases (MMPs) and degrading basement membrane and stroma1.

CD147/EMMPRIN is a member of the immunoglobulin family and is widely expressed in a variety of human tissues and cells1. CD147/EMMPRIN functions to: (1) facilitate secretion of MMP-1, MMP-3, MMP-9 and membrane-type 1-MMP from cancer cells, fibroblasts and endometrial cells, leading to degradation of basement membrane and extracellular matrix, thus promoting tumor proliferation, invasion and metastasis1,2; (2) drive tumor angiogenesis by enhancing MMPs and vascular endothelia growth factor (VEGF) levels in cancer cells and the mesenchyme3; (3) regulate expression and activity of monocarboxylate transporters-1 (MCT-1) and MCT-4, and form complexes on the membrane to transport lactic acid produced by anaerobic glycolysis4; (4) develop chemoresistance in many cancers, probably by mediating activation of phosphatidylinositol 3-hydroxy kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways5,6,7,8; and (5) interact with α3β1, α6β1 integrins to regulate adhesion with extracellular matrix proteins, collagen, laminin or fibronectin and also promote expression of cyclophilin A to induce cancer cell proliferation9. All of these functions are regulated by CD147/EMMPRIN and are summarized in Fig. 1. The outcomes of many of the pathways regulated by CD147 have been associated with the adverse outcomes highlighted in our study.

Figure 1.

Figure 1

Open in a new tab

It is highly upregulated in several malignant tumors10,11,12,13,14,15,16,17. A few recent studies10,15,16,17 have revealed a conflicting correlation between CD147/EMMPRIN and various outcomes in different cancers. A meta-analysis of the literature published previously suggests that elevated MCT-4 and CD147 expressions are associated with worse prognosis across many cancer types focusing on the aspect of tumor metabolism while the existing evidence lacks statistical power to draw a convincing conclusion18. The objective of this updated study was to systematically assemble all the existing CD147 literature, link the data to variable outcomes, perform a comprehensive meta-analysis to predict potential prognostic effects in different cancers, and provide further evidence to establish CD147/EMMPRIN as a key player in tumor progression from a number of perspectives.

Results

Our systematic literature search of CD147 and its correlation with different outcomes identified 910 articles. Among these, 836 articles were excluded and only 82 studies satisfied the inclusion eligibility for the meta-analysis. Upon further review of the full text articles, eight additional articles from reference sources were included. An additional 29 studies were excluded due to the following reasons: two articles were reviews; three were duplicate reports; four had insufficient data; four included only a few cases; nine explored the prognostic value of CD147/EMMPRIN in combination with other biomarkers, such as VEGF, MMP-2, CD44s, MCT-1; and seven studies were determined to be too complicated for subgroup analysis. The remaining 53 studies5,6,7,9,10,11,12,13,14,15,16,17,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59 containing 68 datasets that met our inclusion criteria were included in this review (Fig. 2). Among the eligible studies, 33 provided survival information about the correlation of CD147/EMMPRIN expression with tumor prognosis using a multivariate model and 20 presented the same information using a univariate model. The characteristics of these two models are summarized in Tables 1 and 2, respectively.

Figure 2.

Figure 2

Open in a new tab

Table 1. Characteristics of studies exploring the relationship between CD147/EMMPRIN expression and tumor prognosis (Multivariate model).

Author Year Country Cancer type Stage/grade Number Median (range) Age Follow-up time Median (range) Detection method Cut-off Outcome
Natalie Reimers-10 2004 Germany Breast carcinoma pT1-pT4 600 >50y 63m (1–176m) TMA/IHC score ≥ 1 DSS
HC Zheng-19 2006 Japan Gastric carcinoma 0–IV 219 66.8y (38–88y) 40.4m (0.2m–12.2y) TMA/IHC ≥5% OS
Kazu Ueda-20 2006 Japan Endometrial carcinoma I–IV 112 55.3 ± 11.7 NA IHC score > 2 RFS
Qing Zhang-21 2007 China Hepatocellular carcinoma I–IV 111 47.47 ± 9.55 (24–66y) 26m (30–1880d) IHC ≥1% RFS
Anne B. Als-5 2007 Denmark Bladder Cancer T4b, N2–3, M1 124 62.6y (31–78y) 56.5 (19.5–129.8) m IHC κ values of 0.83 OS
Wulf Sienel-22 2008 Germany Non-small-cell lung cancer T1–T4 57 60y (37–80y) 36 m (4–156) IHC score  > 200 OS
Xingzhu Ju-23 2008 China Cervical Cancer Ib2–IIb 75 49.7y (21–72y) 52m (3–168m) IHC ≥1% DSS
Yu Li-11 2009 China Breast carcinoma infiltrating 106 NA 63.5m (7–170) TMA/IHC ≥30% RFS
Fangfang Liu-12 2010 China Breast carcinoma Invasive 186 52.5y (23–85y) 64.8m (7–170m) IHC ≥1% OS, PFS
Xinjie Yang-24 2010 China Adenoid cystic carcinoma of salivary glands I–IV 72 NA 76.76 ± 37.47 m; (9–178 m) IHC ≥5% OS
Wei-De Zhong-25 2010 China Bladder cancer T1–T4 101 68.1y (46–82y) 36m IHC ≥5% OS, PFS
Tongwei Chu-26 2011 China Pediatric Medulloblastoma M0–M4 (Metastatic stage) 56 Paediatric patients 5–y IHC ≥5% OS
Yijun Xue-27 2011 China Bladder cancer pT1–pT4 108 58.3y (31–82y) 35.5 m (3–86m) TMA/IHC ≥1% OS
Shaojun Zhu-28 2011 China Esophageal Squamous Cell Carcinoma NA 86 40–78y 4–6 y IHC ≥5% OS
Weide Zhong-29 2011 China Prostate cancer pT2–pT3 240 61.81 ± 6.54y/61.94 ± 5.83y NA TMA/IHC ≥5% MFS, OS
Xuecheng Bi-30 2012 China Human seminomas pT1–pT4 65 21.66 ± 10.18y 5 y IHC ≥5% OS
K Boye-31 2012 Norway Colorectal cancer I–III 242 70y (21–98 y) 9.1y (8.2–10.0y) IHC ≥5% MFS, DSS, OS
Zhangxuan Shou-32 2012 China Gastric Cancer I–IV 436 64y (30–91y) >5y TMA/IHC ≥5% OS
Albrecht Stenzinger -33 2012 Germany Colorectal cancer I–IV 285 66.6y NA TMA/IHC score > 6 OS
Shuhua Zhao-13 2013 China Ovarian cancer I–IV 146 52.8y (26–79y) 36m (7–82m) IHC score ≥ 4 OS, PFS
Ying Liu-34 2013 China Breast cancer I–III 189 NA NA IHC ≥10% OS
Anja Rabien-35 2013 Germany Renal cell carcinoma pN0/M0 181 60y (21–86y) 112m (0–194m) TMA/IHC score ≥ 1 OS
Xiaoyan Xu-36 2013 China Non-small lung cancer I–IV 136 60y (35–82y) 28m (1–87m) IHC ≥1% OS
Min Yang-37 2013 China Glioblastoma NA 206 53.6y (14–78y) 12.3 m (1–60 m) IHC score ≥ 1 OS
Yang Zhao-14 2013 China Ovarian carcinomas I–IV 88 51.2y (20–81y) 52m (1–103m) TMA/IHC score ≥ 1 RFS, OS
Qiang Lu-17 2013 China Osteosarcoma IIA–III 55 NA 32m (8–72m) IHC ≥5% OS
Dake Chu-38 2014 China Gastric cancer T1–T4 223 NA 41.8m (DFS)/58.0m (OS) IHC ≥5% OS, PFS
Qin Xu-39 2014 China Cervical carcinoma Ia1–IIb 110 NA NA IHC ≥10% OS, PFS
Shu Zhao-40 2014 China Breast cancer I–III 127 49y (30–68y) NA IHC ≥10% OS, PFS
Naohisa Futamura-16 2014 Japan Osteosarcoma IIA–IIB 53 20y (4–57y) 72m (8–200m) IHC score ≥ 1 OS, DFS
Jian Gao-43 2014 China Ovarian cancer I–IV 92 NA NA IHC ≥5% OS
Luís Silva Monteiro-15 2014 Portugal Oral squamous cell carcinomas I–IV 74 62.3 ± 15.3y (25–96y) 36.45 ± 31.7m TMA/IHC score > 3 CSS
Shaojun Zhu-41 2015 China Hepatocellular carcinoma NA 50 31–76y 4y IHC ≥5% OS
Open in a new tab

Table 2. Characteristics of studies exploring the relationship between CD147/EMMPRIN expression and tumor prognosis (Univariate model) V.

Author Year Country Cancer type Stage/grade Number Age Median (range) Follow-up time Median (range) Detection method Cut-off Outcome
Hai-Gang Li-42 2005 China Hepatocellular carcinoma grade1–4 51 51 ± 11y (24–69y) 26m (5–90m) IHC ≥10% DFS
Wen-Chiuan Tsai -43 2006 China Renal cell carcinoma I–IV 100 NA 5–year TMA/IHC score > 130 OS
Nobuyuki Hakuma-44 2007 Japan Non-Small Cell Lung Cancers stage I 95 62.8 ± 9.1 5–y IHC score > 3 OS
Wen Chiuan Tsai-45 2007 China Pancreatobiliary adenocarcinoma T4 70 NA 2–y IHC score > 100 OS
Wei Wu-46 2008 China Gallbladder carcinoma I–IV 108 51.63 ± 10.08y (35–76y) 5–9y IHC ≥5% OS
Daniel Buergy-47 2009 Germany Colorectal Cancer I–IV 40 NA 30 months IHC ≥5% DSS
Ziming Du-48 2009 China Nasopharyngeal carcinoma I–IV 157 46y (14–86y) 5–y TMA/IHC ≥5% OS
Zhaodong Han-49 2010 China Renal/Bladder/Prostate carcinoma I–IV 52/58/101 57.26 ± 11.2y 1–5y IHC ≥5% OS
H. Z. Zeng-7 2011 China Non-small-cell lung cancer III/IV 118 NA NA IHC ≥25% OS
Congfa Huang-9 2012 China Tongue squamous cell carcinoma I–IV 80 NA 69m (2–106m) IHC ≥10% OS
Larissa Sweeny-50 2012 USA Cutaneous Squamous Cell Carcinoma III–IV 56 72 ± 12 (42–91) >2y IHC ≥25% OS
Keiichiro Nakamura-51 2012 Japan Endometrial cancer I–IV 134 57.7y (28–85) NA IHC ≥10% DFS, OS
Mototaka Sato-52 2013 Japan Renal cell carcinoma I–IV 50 27–82 (62) 52 (1–114 m) IHC score ≥ 1 OS, PFS
Wen Chiuan Tsai-53 2013 China Astrocytomas III–IV 77 NA NA GDS1962 database 1,500 OS
Qing Yang-54 2013 China Hypopharyngeal Squamous Cell Carcinoma I–IV 80 60.73y (42–78)   IHC ≥P90 level RFS
Xinwen Zhong-55 2013 China Lung cancer T1 180 60y (37–75y) 60m (3–96m) IHC ≥25% OS
Jung-Woo Choi-56 2014 Korea Urothelial carcinoma of the bladder Ta–T4 360 69y (23–97y) 36m TMA/IHC score > 16 OS
Xin-Qiong Huang-57 2014 China Cervical squamous cell carcinoma IB-IVA 132 51y (28–80y) 45m (2–85.5m) IHC ≥5% PFS
Céline Pinheiro-58 2014 Portugal Soft tissue sarcomas I–III 84 NA NA IHC score ≥ 3 OS
Younghye Kim-59 2015 Korea Clear cell renal cell carcinoma I–IV 180 25–83y (58y) 40.7m (1–173) TMA/IHC score > 17 PFS
Open in a new tab

The 53 eligible studies represented 26 different carcinomas or sarcomas and a median number of 204.5 patients (range, 40–600). CD147/EMMPRIN expression in these studies was mainly detected by immunohistochemistry (IHC). One publication had three groups of subjects from different cancers and was therefore considered as three different studies49. Ten publications12,13,14,16,25,29,38,39,51,52 presented two different prognostic results, while one publication31 presented three prognostic results. Some studies also investigated the link between CD147/EMMPRIN and chemotherapy5,6,7 or radiation resistance57. In terms of clinicopathological variables, most of the studies suggested that increased CD147/EMMPRIN expression correlated significantly with higher clinical grade, tumor size, invasion depth, lymphatic invasion, histological grade, and some additional parameters (Table 3).

Table 3. Relationship between CD147/EMMPRIN overexpression and clinical and pathological factors.

Author Cancer type Relative to other factors Relative to clinicopathologic variables
Multivariate
Natalie Reimers-10 Breast carcinoma ER, PR (inversely) High tumor grade, histologically determined mitotic index, tumor size, inversely correlated to age
HC Zheng-19 Gastric carcinoma ki-67, MMP-2, MMP-9, VEGF, MVD Tumour size, depth of invasion, lymphatic invasion, not with lymph node metastasis, UICC staging or differentiation
Kazu Ueda-20 Endometrial carcinoma   Advanced stage, poorly differentiated carcinoma, lymph node metastasis, lymphatic vessel infiltration, pathological high risk group
Qing Zhang-21 Hepatocellular carcinoma MVD-CD34; MMP-2 in pericancerous, not in cancerous lesions; VEGF pTNM tumor stages, tumor size and venous invasion, IV stage and large tumor size, preoperative AFP level; not: viral hepatitis, the number of tumor nodules, lymph node metastasis
Anne B. Als-5 Bladder Cancer   Visceral metastases
Wulf Sienel-22 Non-small-cell lung cancer MMP-2 (no), MMP-9 (no)  
Xingzhu Ju-23 Cervical Cancer   Pelvic lymph node metastasis, no correlation with clinical stage and histopathology
Yu Li-11 Breast carcinoma    
Fangfang Liu-12 Breast carcinoma C-erbB-2; ER, PR (inversely) Histological grade, local recurrence, distant metastasis and tumor mortality
Xinjie Yang-24 Adenoid cystic carcinoma of salivary glands MMP-2, MMP-9, VEGF, Ki-67 index, MVD Tumor size, histotypes, clinical stage, perneural invasion, vascular invasion, metastasis
Wei-De Zhong-25 Bladder cancer   Tumor stage and grade, status of carcinoma in situ, tumor recurrence, tumor progression
Tongwei Chu-26 Pediatric Medulloblastoma   Higher metastatic stage, aggressive histopathological type, necrosis, undifferentiated tumor
Yijun Xue-27 Bladder cancer   Lymph node status, tumor stage, histologic grade
Shaojun Zhu-28 Esophageal Squamous Cell Carcinoma   Lymph node metastasis cases, differentiation, depth of tumor invasion
Weide Zhong-29 Prostate cancer   Gleason score, positive surgical margin status, reduced PSA failure-free survival
Xuecheng Bi-30 Human seminomas MMP-2 advanced T, N and M stage, poor differentiation types
K Boye-31 Colorectal cancer S100A4 no associations with any of the clinical or histopathological parameters
Zhangxuan Shou-32 Gastric Cancer ADAM17 Age, tumor size, location, depth of invasion, TNM stage, Lauren’s classification, vessel invasion, and lymph node and distant metastasis of tumor
Albrecht Stenzinger -33 Colorectal cancer   Trend correlation with stage, distant metastasis, blood vessel invasion, and Dukes classification
Shuhua Zhao-13 Ovarian cancer   Lymph-vascular space involvement, lymph node metastasis
Ying Liu-34 Breast cancer    
Anja Rabien-35 Renal cell carcinoma   pT stage and Fuhrman grading
Xiaoyan Xu-36 Non-small lung cancer   Tumor diameter, lymph node status, tumor stage
Min Yang-37 Glioblastoma   Karnofsky performance status (KPS) score
Yang Zhao-14 Ovarian carcinomas Ki-67 FIGO staging, dedifferentiation
Qiang Lu-17 Osteosarcoma   Pathological classification, percentage of dead cells
Dake Chu-38 Gastric cancer   Invasion, metastasis and TNM stage
Qin Xu-39 Cervical carcinoma   FIGO clinical stage, lymph node metastasis, parametrium invasion, and differentiation
Shu Zhao-40 Breast cancer MMP-9, Ki67 Lymph node metastasis, high pathological grade, tumor size larger than 2 cm
Naohisa Futamura-16 Osteosarcoma MT1-MMP Not associated with age, gender, anatomic location, necrosis after neoadjuvant chemotherapy, or surgical stage
Jian Gao-43 Ovarian cancer Lewis y antigen Drug-resistant
Luís Silva Monteiro-15 Oral squamous cell carcinomas Ki-67 Advanced tumor stages, histological grade
Shaojun Zhu-41 Hepatocellular carcinoma   No relationship between differentiation, HBV infection, significantly opposite to cirrhosis
Univariate
Hai-Gang Li-42 Hepatocellular carcinoma paxillin and syndecan-1 (no) Not associated with serum AFP level, HBsAg status, presence of microsatellite nodule, tumor size, presence of cirrhosis and necrosis, differentiation, presence of portal vein thrombosis and extra-hepatic metastasis
Wen-Chiuan Tsai -43 Renal cell carcinoma fascin Histological grades and clinical stages
Nobuyuki Hakuma-44 Non-Small Cell Lung Cancers   Well differentiated, not associated with any of the following variables: age, gender, histology, pT or pN classification, and pathological stage
Wen Chiuan Tsai-45 Pancreatobiliary adenocarcinoma fascin Histologic grades and clinical stages
Wei Wu-46 Gallbladder carcinoma MMP-2 Nevin stages of tumor tissues, histological differentiated degree, distant metastasis
Daniel Buergy-47 Colorectal Cancer   pT or pN status, metastasis
Ziming Du-48 Nasopharyngeal carcinoma Cav-1 Metastasis of the disease
Zhaodong Han-49 Renal/Bladder/Prostate carcinoma   TNM stages, histological subtypes
H. Z. Zeng-7 Non-small-cell lung cancer   No association (overall CD147); (membranous CD147) associated with a poor response to chemotherapy
Congfa Huang-9 Tongue squamous cell carcinoma HIF-1a, VEGF-A, VEGF-C, CypA Recurrence and node metastasis
Larissa Sweeny-50 Cutaneous Squamous Cell Carcinoma   Node positive disease
Keiichiro Nakamura-51 Endometrial cancer   FIGO stage, histology, depth of myometrial invasion, cervical involvement, lymph node metastasis, lymph vascular space involvement, peritoneal cytology
Mototaka Sato-52 Renal cell carcinoma anti-CD34 Pathological T stage, clinical M stage, AJCC stage, Fuhrman grade, microvessel area of immature vessels
Wen Chiuan Tsai-53 Astrocytomas   WHO grades
Qing Yang-54 Hypopharyngeal Squamous Cell Carcinoma CD44v6; COX-2 T classification, lymph node metastasis and clinical stage
Xinwen Zhong-55 Lung cancer RACK1 Differentiation, Lymph node metastasis
Jung-Woo Choi-56 Urothelial carcinoma of the bladder MCT1, MCT4 High World Health Organization grade, advanced tumor node metastatis stage, and nonpapillary growth type
Xin-Qiong Huang-57 Cervical squamous cell carcinoma GLUT-1 Histopathological grade, Tumor diameter, radiation-resistant
Céline Pinheiro-58 Soft tissue sarcomas MCT1, MCT4 Disease progression
Younghye Kim-59 Clear cell renal cell carcinoma   High grade, tumor necrosis, larger tumor size
Open in a new tab

CD147/EMMPRIN and overall survival (OS)

The 44 studies, with data from a total of 5,813 patients, showed that CD147/EMMPRIN expression was associated with worse OS, both in multivariate (meta-hazard ratio (HR) = 1.92; 95% confidence interval (CI): 1.58–2.32) and in univariate models (meta-HR = 1.98; 95% CI: 1.53–2.57) (Table 4; Fig. 3A,B). In addition, separate analysis of solid and non-solid tumors suggested that the OS of solid tumors was significantly associated with CD147 in both multivariate (meta-HR = 1.73; 95% CI: 1.44–2.08) and univariate (meta-HR = 2.06; 95% CI: 1.57–2.70) models. In contrast, OS of non-solid tumors only displayed significant association in the multivariate model (meta-HR = 3.72; 95% CI: 2.23–6.22), while there was no significant association in the univariate model analysis (meta-HR = 1.34, 95% CI: 0.77–2.32) (Table 4).

Table 4. Meta-analysis of association between CD147/EMMPRIN expression and tumor prognosis.

  OS
 PFS
 DSS
      
No/case meta-HR (95CI%) P* I2 (P#) No/case meta-HR (95CI%) P* I% (P#) No/case meta-HR (95CI%) P* I2 (P#)      
Multivariate      
Total 27/3933 1.92 (1.58–2.32) 0.000 66.4 (0.000) 13/1845 2.32 (1.67–3.21) 0.000 56.3 (0.007) 4/991 1.83 (1.27–2.65) 0.001 0.00 (0.458)      
Solid tumor 23/3563 1.73 (1.44–2.08) 0.000 60.7 (0.000) 12/1792 2.26 (1.61–3.18) 0.000 58.5 (0.005) 4/991 1.83 (1.27–2.65) 0.001 0.00 (0.458)      
Nun-solid tumor 4/370 3.72 (2.23–6.22) 0.000 36.6 (0.192) 1/53 3.52 (1.18–10.5) 0.024   0      
Breast carcinoma 5/695 2.92 (1.85–4.60) 0.000 5.00 (0.378) 3/419 2.50 (1.63–3.83) 0.000 0.00 (0.846)        
Bladder cancer 3/333 2.32 (1.63–3.29) 0.000 0.00 (0.860)          
Gastric carcinoma 3/878 1.33 (0.99–1.80) 0.060 62.0 (0.072)          
Colorectal cancer 2/527 2.14 (1.38–4.26) 0.035 77.9 (0.033)          
Ovarian cancer 3/326 1.57 (1.23–2.01) 0.000 0.00 (0.982) 2/234 1.72 (1.23–2.40) 0.002 0.00 (0.833)        
Osteosarcoma 2/108 7.83 (3.18–19.27) 0.000 0.00 (0.852)          
Total publish bias 0.05 (Begg’ test) 0.007 (Egger’ test) 0.300 (Begg’ test) 0.259 (Egger’ test) 0.734 (Begg’ test) 0.469 (Egger’ test)      
Univariate      
Total 17/1880 1.98 (1.53–2.57) 0.000 89.3 (0.000) 6/627 2.18 (1.30–3.63) 0.003 96.7 (0.000) 1/40 5.81 (4.16–7.46) 0.037        
Solid tumor 15/1719 2.06 (1.57–2.70) 0.000 90.4 (0.000) 6/627 2.18 (1.30–3.63) 0.003 96.7 (0.000) 1/40 5.81 (4.16–7.46) 0.037        
Nun-solid tumor 2/161 1.34 (0.77–2.32) 0.300 2.90 (0.310) 0 0      
Renal cell carcinoma 3/202 1.87 (1.37–2.56) 0.000 70.9 (0.032) 2/230 1.58 (1.34–1.85) 0.000 0.00 (0.91)        
Lung Cancer 3/393 1.16 (0.63–2.12) 0.630 74.1 (0.021) — —      
Bladder carcinoma 2/418 2.51 (1.46–4.33) 0.001 81.9 (0.019) — —      
Total publish bias 0.773 (Begg’ test) 0.228 (Egger’ test) −0.707 (Begg’ test) −0.304 (Egger’ test)        
Open in a new tab

P* present P for HR, P# present P for I2.

Figure 3. Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and overall survival (OS) in cancer patients.

Figure 3

Open in a new tab

Panel A, represents the association of CD147/EMMPRIN positive expression with worse OS in multivariate model, while panel B, represents similar association by univariate model.

Furthermore, the subgroup analysis of tumors stratified by cancer type also demonstrated a significant association between higher CD147/EMMPRIN expression and adverse outcome of OS for breast carcinoma (meta-HR = 2.92; 95% CI: 1.85–4.60), bladder cancer (meta-HR = 2.32; 95% CI: 1.63–3.29), colorectal cancer (meta-HR = 2.14; 95% CI: 1.38–4.26), ovarian cancer (meta-HR = 1.57; 95% CI: 1.23–2.01) and osteosarcoma (meta-HR = 7.83; 95% CI: 3.18–19.27) in the multivariate model. However, an association was only observed in renal cell carcinoma (meta-HR = 1.87; 95% CI: 1.37–2.56) and bladder carcinoma (meta-HR = 2.51; 95% CI: 1.46–4.33), using the univariate model. In contrast, there was no association in gastric carcinoma (meta-HR = 1.33; 95% CI: 0.99–1.80) and lung cancer (meta-HR = 1.16; 95% CI: 0.63–2.12) (Table 4). We also found a similar association of CD147 with the adverse outcome (OS) in many other cancers, such as adenoid cystic carcinoma of salivary glands, esophageal squamous cell carcinoma, prostate cancer, pediatric medulloblastoma, glioblastoma, gallbladder carcinoma, nasopharyngeal carcinoma, tongue squamous cell carcinoma, endometrial cancer, uterine cervical carcinoma, hepatocellular carcinoma, pancreatobiliary adenocarcinoma, cutaneous squamous cell carcinoma, astrocytomas and soft tissue sarcomas (Supplementary Figure 1A,B).

CD147/EMMPRIN and progression free survival (PFS), metastasis-free survival (MFS) and recurrence-free survival (RFS)

Analysis of 19 studies, with a total of 2,472 patients, showed that CD147/EMMPRIN expression was associated with worse PFS/MFS/RFS, both in multivariate (meta-HR = 2.32; 95% CI: 1.67–3.21) and univariate (meta-HR = 2.18; 95% CI: 1.30–3.63) models (Table 3 and Fig. 4A,B). Moreover, the HR estimates derived specifically from the solid tumors by both models showed a similar pattern of association (multivariate: meta-HR = 2.26; 95% CI: 1.61–3.18; univariate: meta-HR = 2.18; 95% CI: 1.30–3.63). Exclusive analysis of non-solid tumors by a multivariate model suggested a significant association (meta-HR = 3.52; 95% CI: 1.18–10.5) (Table 4).

Figure 4. Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and PFS/MFS/RFS in cancer patients.

Figure 4

Open in a new tab

Panel (A) represents the overall association of CD147/EMMPRIN positive expression with worse PFS/MFS/RFS in multivariate model; panel (B) depicts similar association in univariate model.

Similarly, the subgroup analysis of tumors stratified by cancer type again demonstrated a significant association between CD147/EMMPRIN overexpression and adverse outcome of PFS/MFS/RFS in breast carcinoma (meta-HR = 2.50; 95% CI: 1.63–3.83) and ovarian cancer (meta-HR = 1.72; 95% CI: 1.23–2.40) in the multivariate model and renal cell carcinoma (meta-HR = 1.58; 95% CI: 1.34–1.85) in the univariate model. Similar associations were observed in hepatocellular carcinoma, bladder cancer, prostate cancer, colorectal cancer, osteosarcoma, gastric cancer and hypopharyngeal squamous cell carcinoma. However, we did not observe an association in cases of endometrial carcinoma, and the results were not consistent for cervical carcinoma (Supplementary Figure 2A,B).

CD147/EMMPRIN and disease-specific survival (DSS)

Quantitative analysis of five different studies, representing 1,031 patients, linked CD147/EMMPRIN overexpression with DSS in four different solid tumors, namely breast cancer2, colorectal cancer [24, 41], oral squamous cell carcinomas7 and cervical cancer16. Multivariate model analysis established that CD147/EMMPRIN expression was associated with a worse DSS (meta-HR = 1.83; 95% CI: 1.27–2.65) (Table 4; Fig. 5A). Similarly, univariate model analysis indicated that CD147 expression associated with worse DSS (meta-HR = 5.81; 95% CI: 4.16–7.46) (Table 4). This pattern was unchanged even in the subgroup analyses stratified by cancer type. Multivariate model analysis also identified the following associations with DSS: breast carcinoma (meta-HR = 1.70; 95% CI: 1.02–2.84), oral squamous cell carcinoma (meta-HR = 3.89; 95% CI: 1.11–13.71) and colorectal cancer (meta-HR = 2.30; 95% CI: 1.03–5.14). The only cancer for which we did not observe an association was uterine cervical carcinoma (meta-HR =1.23; 95% CI: 0.52–2.90) (Supplementary Figure 4).

Figure 5. Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and disease free survival (DSS) in cancer patients, and to predict easier recurrence of drug resistance.

Figure 5

Open in a new tab

Panel A, represents the association of CD147/EMMPRIN positive expression with worse DSS in multivariate model. Panels B, represents the potential of CD147/EMMPRIN positive expression to predict easier recurrence of drug resistance.

CD147/EMMPRIN and chemotherapy drug/radiation resistance

Among the included articles, three studies5,6,7 reported risk for CD147/EMMPRIN overexpression and chemotherapy drug resistance, while only one study57 reported radiation resistance. Quantitative analysis of three articles revealed that positive expression of CD147/EMMPRIN predicted recurrence of drug resistance (meta-OR = 9.30; 95% CI: 2.09–41.30) (Fig. 5B). In addition, CD147/EMMPRIN overexpression appeared to be linked to high risk of radiation resistance (OR = 13.30; 95% CI: 4.38–40.35) in cervical squamous cell carcinomas, although this is just based on one study (Fig. 5C).

Heterogeneity analysis

There was evidence of significant heterogeneity (I2 > 50%) between OS and PFS studies, but not among DSS studies (Table 4). Therefore, the random-effect model was used in all analyses except for the DSS. For the OS and PFS studies, we conducted a meta-regression analysis using publication year, cancer type, sample size, and country as covariates. All covariates were entered into the meta-regression model simultaneously, and the covariates with the highest p values were omitted one at a time to identify sources of heterogeneity. The meta-regression did not identify any of these covariates as a significant source of heterogeneity for OS and PFS studies in multivariate, and indicated that cancer type may be the source of heterogeneity for OS studies in univariate analysis (Coef = 0.093, p = 0.042) (Supplementary Figure 4). Meta-regression was not used for univariate analysis of the PFS since these studies numbered less than 10.

Sensitivity analysis

We also performed a sensitivity analysis to evaluate the effects of individual studies on the pooled HR estimates by omitting one study at a time. The HR estimates for the DSS and PFS/MFS/RFS in the multivariate model were not altered. However, the HR estimates for the OS in the multivariate model, and OS and PFS/MFS/RFS in the univariate model were altered when one, one and two studies were excluded, respectively (data not shown).

Publication bias

To assess confidence in our study, we performed a publication bias analysis using the funnel plot and Egger’s and Begg’s rank correlation tests. There was no significant publication bias in both models for the DSS and PFS/MFS/RFS groups (Table 4; Fig. 6D–F). In the case of the OS group, the univariate model (Table 4; Fig. 6C) suggested no publication bias, but in the multivariate model, results were inconsistent based on the p value obtained by Begg’s rank test (0.05) and Egger’s test (0.007) (Table 4; Fig. 6A). These test results were nonparametric and therefore the Trim and Fill method was used to further verify this analysis. After filling the deleted studies (square dots), we found no obvious asymmetry in the funnel plot (Fig. 6B). Thus, the HR estimates for the prognostic value of CD147/EMMPRIN were not notably altered (data not shown). This suggests that there was no publication bias even in the OS group in the multivariate model.

Figure 6. Assessment of publication bias for OS, DSS, and PFS/MFS/RFS studies.

Figure 6

Open in a new tab

Panel (A) depicts the assessment of publication bias for multivariate model studies, by funnel plot analysis, whereas panel (B) shows funnel plot analysis using nonparametric Trim and Fill method. Panel (C) represents the publication bias in univariate model studies. Panel (D) represents the assessment of publication bias for multivariate model. Panels (E,F) represents assessment of publication bias for multivariate and univariate model studies, respectively.

Discussion

CD147/EMMPRIN is a glycosylated, multifunctional molecule that participates in tumor progression61. In the present study, we quantitatively analyzed the data from 53 studies, including 68 datasets, to examine the associations between CD147/EMMPRIN expression and its prognosis predictive value in cancer. Previous studies have suggested that combination of CD147/EMMPRIN with other factors, especially VEGF60,62,63 and MMP-264,65,66, can predict the prognosis of some cancers. Here, we exclusively studied the role of CD147/EMMPRIN in tumor prognosis. Our meta-analysis revealed that the prognosis in three adverse outcomes was significantly poor in cases with CD147/EMMPRIN overexpression. This was further confirmed in subgroup analyses of tumors stratified by cancer type. Meanwhile, the predictive role of CD147/EMMPRIN in cervical cancer and hepatocellular carcinoma prognosis has been controversial and its result in cervical carcinoma, endometrial carcinoma, pancreatobiliary adenocarcinoma and some additional tumors did not consistently reach significance. However, the sample size and studies in our stratified analysis were small, and our findings should be further verified.

CD147/EMMPRIN has been shown to be involved in the regulation of tumor cell invasion, metastasis, angiogenesis, anti-apoptosis, adhesion and facilitation of drug resistance through its association with various proteins1, such as MMP-219, MMP-920, Ki-6714, VEGF19, microvessel density19, C-erbB-212, S100A431, a disintegrin and metalloproteinase 1732, lewis y antigen6, fascin43, caveolin-148, hypoxia inducible factor 1 alpha9, cyclophilin A9, CD44v654, cyclooxygenase-254, receptor for activated C kinase 155 and metabolism related factors like MCT-156, MCT-456, and glucose transporter -157. However, there is some conflicting literature refuting associations with paxillin42, syndecan-142, and MMP-2 and MMP-922. In addition, CD147 expression has been proposed to inversely correlate with estrogen and progesterone expression10,12. Furthermore, CD147/EMMPRIN was positively associated with clinicopathological variables in most studies (Table 3). It is speculated that CD147/EMMPRIN interacting with many proteins representing various molecular or biological pathways contributes to malignant progression, eventually causes adverse clinical outcomes.

Previous meta-analyses didn’t explore any significant association between CD147/EMMPRIN and susceptibility of radio-chemotherapy. In the view of more studies are warranted to validate CD147/EMMPRIN association with chemotherapy and radiation resistance prediction5,6,7,57. It has been suggested that chemotherapy drugs combined with CD147-targeted therapy may increase the sensitivity of tumor cells to several different chemotherapeutics, and can result in more effective inhibition of tumor proliferation and recurrence7,67. Our study also established that increased CD147/EMMPRIN expression is linked to high risk of drug resistance and our preliminary analysis linked CD147 to radiation resistance. It follows that CD147/EMMPRIN has been proposed to be an important potential therapeutic target.

The results of the present study must be interpreted with caution due to the presence of substantial heterogeneity. In addition, there were several limitations in this study. First, the composition of the cancer type or stage varied between studies, and the detection and corresponding cut-offs varied. For instance, some studies only included pediatric patients26 while others included older patients10. Also, in non-small-cell lung cancer, CD147/EMMPRIN was associated with poor survival in patients with adenocarcinoma only, but not with squamous cell carcinoma22. The scoring criteria were also inconsistent. Second, the follow-up time varied across studies, which may have contributed to the non-homogeneity of prognostic information. Sensitivity analysis results also showed instability within individual articles. Third, this study was based on published articles only and, since negative data are hard to publish, there could be publication bias, which is an inherent limitation of all meta-analyses, irrespective of outcomes from the Egger’s linear regression test and Begg’s rank correlation test.

Conclusion

In summary, this meta-analysis indicated that higher expression of CD147/EMMPRIN potentially may be a prognostic marker for most cancers, and thus can serve as a potential therapeutic target. We further verified that CD147/EMMPRIN had a complex role in tumor progression by crosstalk with numerous factors. However, additional multicenter prospective studies are warranted to confirm these findings, especially in various types of tumors.

Methods

Study identification

We searched PubMed and Embase databases through March 2015 to identify relevant studies for inclusion in our meta-analysis. The following keywords were used in the literature searches; “CD147”, “extracellular matrix metalloproteinase inducer”, “EMMPRIN”, “basigin”, “survival”, “prognosis”, “tumor”, “cancer”, “carcinoma”, “neoplasm”, or their combinations. Eligible articles were selected based on title, abstract and full text. If the same patient cohort was reported in multiple publications, only the most complete and most recent publication was selected. We also searched of the reference lists from electronically identified articles.

Inclusion and exclusion criteria

Based on the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines, we included studies that met all of the following criteria: (1) written in English; (2) reported quantitative outcomes from prognostic association studies of tumor and CD147/EMMPRIN; (3) described outcomes as overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), metastasis-free survival (MFS) or recurrence-free survival (RFS), depending upon the study; (4) had a minimum of 40 case numbers describing prognosis; (5) provided a detailed protocol, including the source of raw materials, methodology, quantification methods, and scoring criteria; (6) precisely defined the time-to-event outcome, time to follow-up, and the median follow-up time; and (8) data were presented as the estimated hazard ratios (HRs) with 95% confidence intervals (CIs) or in the case where HRs or 95% CIs were not reported directly, a calculation was used to determine if the conditions of the study were suitable for inclusion68. Multivariate analyses were used for statistical analysis biomarkers that had independent prognostic factors for cancers after adjusting for one or more additional standard clinical prognostic variables like age, pathology, stage, grade, lymphatic metastasis or other biological marker variables. Studies were excluded if they were case reports, case-only studies, letters, reviews, reported insufficient data, lacked statistical analysis, combined with other factors, or were duplicate studies. All studies were independently reviewed by two authors, and in a case of conflict a third author resolved the issue after thorough discussion.

Data collection and analysis

We assessed heterogeneity using the Chi2 test and I2 test69. If heterogeneity was present, meta-regression was used to determine the source. We combined data from different trials using a fixed-effect model when there was no significant heterogeneity in populations (I2 < 50%) and a random-effect model when there was considerable heterogeneity. If heterogeneity was present, meta-regression was used to determine the source. Variables were synthesized using HR/OR. By convention, an overall HR (OR) > 1 with a 95% CI implied a poor outcome (high risk) for the group with either positive or negative biomarker expression. The high HR value corresponded with poor survival. To evaluate the effects of individual studies on the pooled HR estimates, we performed a sensitivity analysis omitting one study at a time. The statistical significance was set at 0.05. We used funnel plot asymmetry using Egger’s linear regression test and Begg’s rank correlation test to assess the publication bias. If both test results were inconsistent, Nonparametric Trim and Fill method was used to verify the results70. A P value of <0.05 suggested significant publication bias. All statistical analyses were performed using STATA 12.0 (StataCorp, College Station, TX) statistical software.

Additional Information

How to cite this article: Xin, X. et al. CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis. Sci. Rep. 6, 32804; doi: 10.1038/srep32804 (2016).

Supplementary Material

Supplementary Information
srep32804-s1.doc (21.5MB, doc)

Footnotes

Author Contributions X.Y.X., X.Q.Z., H.J.G. and H.B.W. conceived and designed the experiments; X.Y.X., X.Q.Z., H.J.G., M.L., H.M.T., Z.S.J., T.H., R.S. and H.B.W. performed the experiments; X.Y.X., X.Q.Z., H.J.G., H.M.T., Z.S.J. and H.B.W. analyzed the data; X.Y.X., X.Q.Z., H.J.G., M.L., T.H., R.S. and H.B.W. contributed resources to facilitate the analyses; X.Y.X. and H.B.W. wrote the paper.

References

  1. Huang P. et al. RNA interference targeting CD147 inhibits the proliferation, invasiveness, and metastatic activity of thyroid carcinoma cells by down-regulating glycolysis. Int J Clin Exp Pathol. 8, 309–318 (2015). [PMC free article] [PubMed] [Google Scholar]
  2. Grass G. D. & Toole B. P. How, with whom and when: an overview of CD147 mediated regulatory networks influencing matrix metalloproteinase activity. Biosci Rep. 24, 36(1) (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Pinheiro C. et al. Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas. BMC Cancer. 15, 835 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Li S., Nguyen T. T. & Bonanno J. A. CD147 required for corneal endothelial lactate transport. Invest Ophthalmol Vis Sci. 55, 4673–81 (2014) [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Als A. B. et al. Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer. Clin Cancer Res. 13, 4407–4414 (2007). [DOI] [PubMed] [Google Scholar]
  6. Gao J. et al. Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance. Med Oncol. 31, 920–928 (2014). [DOI] [PubMed] [Google Scholar]
  7. Zeng H. Z. et al. Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance. Neoplasma. 58, 449–454 (2011). [DOI] [PubMed] [Google Scholar]
  8. Hao J. et al. In vitro and In vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. PLoS ONE. 7, e40716 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Huang C. et al. Association of increased ligand cyclophilin A and receptor CD147 with hypoxia, angiogenesis, metastasis and prognosis of tongue squamous cell carcinoma. Histopathology. 60, 793–803 (2012). [DOI] [PubMed] [Google Scholar]
  10. Reimers N. et al. Expression of Extracellular Matrix Metalloproteases Inducer on micrometastatic and primary mammary carcinoma cells. Clinical Cancer Research. 10, 3422–3428 (2004). [DOI] [PubMed] [Google Scholar]
  11. Li Y. et al. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology. 54, 677–687 (2009). [DOI] [PubMed] [Google Scholar]
  12. Liu F. et al. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat. 124, 677–688 (2010). [DOI] [PubMed] [Google Scholar]
  13. Zhao S. H. et al. Basigin-2 is the predominant basigin isoform that promotes tumor cell migration and invasion and correlates with poor prognosis in epithelial ovarian cancer. Journal of Translational Medicine. 11, 92–103 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Zhao Y. et al. The role of EMMPRIN expression in ovarian epithelial carcinomas. Cell Cycle. 17, 2899–2913 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Monteiro L. S. et al. EMMPRIN Expression in Oral Squamous Cell Carcinomas: Correlation with Tumor Proliferation and Patient Survival. BioMed Research International. 1–9 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Futamura N. et al. EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients with osteosarcoma. Tumor Biol. 35, 5159–5165 (2014). [DOI] [PubMed] [Google Scholar]
  17. Lu Q., Lv G., Kim A., Ha J. M. & Kim S. Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma. Oncology Letters 5, 201–207 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Bovenzi C. D. et al. Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis. Biomed Res Int. 2015, 242437 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Zheng H. C. et al. Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasionand prognosis. British Journal of Cancer. 95, 1371–1378 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ueda K. et al. Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3. Oncology Reports. 17, 731–735 (2007). [PubMed] [Google Scholar]
  21. Zhang Q. et al. Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. European Journal of Cancer Prevention. 16, 196–202 (2007) [DOI] [PubMed] [Google Scholar]
  22. Sienel W. et al. Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Modern Pathology. 21, 1130–1138 (2008). [DOI] [PubMed] [Google Scholar]
  23. Ju X. Z., Yang J. M., Zhou X. Y., Li Z. T. & Wu X. H. EMMPRIN Expression as a Prognostic Factor in Radiotherapy of Cervical Cancer. Clin Cancer Res. 14, 494–501 (2008). [DOI] [PubMed] [Google Scholar]
  24. Yang X. et al. Expression of EMMPRIN in adenoid cystic carcinoma of salivary glands: correlation with tumor progression and patients’ prognosis. Oral Oncology. 46, 755–760 (2010). [DOI] [PubMed] [Google Scholar]
  25. Zhong W. D. et al. Extracellular matrix metalloproteinase inducer expression has an impact on survival in human bladder cancer. Cancer Epidemiology. 34, 478–482 (2010). [DOI] [PubMed] [Google Scholar]
  26. Chu T., Chen X., Yu J., Xiao J. & Fu Z. Extracellular Matrix Metalloproteinase Inducer is a Negative Prognostic Factor of Pediatric Medulloblastoma. Pathol. Oncol. Res. 17, 705–711 (2011). [DOI] [PubMed] [Google Scholar]
  27. Xue Y. J., Lu Q. & Sun Z. X. CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer. Med Oncol. 28, 1363–1372 (2011). [DOI] [PubMed] [Google Scholar]
  28. Zhu S. et al. Clinical Impact of HAb18G/CD147 Expression in Esophageal Squamous Cell Carcinoma. Dig Dis Sci. 56, 3569–3576 (2011). [DOI] [PubMed] [Google Scholar]
  29. Zhong W. D. et al. Expression of CD147 is associated with prostate cancer progression. Int. J. Cancer. 130, 300–308 (2012). [DOI] [PubMed] [Google Scholar]
  30. Bi X. C. et al. Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas. Clin Transl Oncol. 14, 190–196 (2012). [DOI] [PubMed] [Google Scholar]
  31. Boye K. et al. EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer. British Journal of Cancer. 107, 667–674 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Shou Z. X., Jin X. & Zhao Z. S. Upregulated Expression of ADAM17 Is a Prognostic Marker for Patients With Gastric Cancer. Ann Surg. 256, 1014–1022 (2012). [DOI] [PubMed] [Google Scholar]
  33. Stenzinger A. et al. High extracellular matrix metalloproteinase inducer/CD147expression is strongly and independently associated with poor prognosis in colorectal cancer. Human Pathology. 43, 1471–1481 (2012). [DOI] [PubMed] [Google Scholar]
  34. Liu Y. et al. CD147, MMP9 expression and clinical significance of basal-like breast cancer. Med Oncol. 30, 366 (2013). [DOI] [PubMed] [Google Scholar]
  35. Rabien A. et al. Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis. Journal of Translational Medicine. 11, 258 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Xu X. Y., Lin N., Li Y. M., Zhi C. & Shen H. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non- small cell lung cancer. Pathology Research and Practice. 209, 345–352 (2013). [DOI] [PubMed] [Google Scholar]
  37. Yang M. et al. Prognostic significance of CD147 in patients with glioblastoma. J Neurooncol. 115, 19–26 (2013). [DOI] [PubMed] [Google Scholar]
  38. Chu D. et al. CD147 Expression in Human Gastric Cancer Is Associated with tumor recurrence and prognosis. PLOS ONE. 9, e101027 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Xu Q. et al. ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma. Tumor Biol. 35, 7575–7586 (2014). [DOI] [PubMed] [Google Scholar]
  40. Zhao S. et al. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med Oncol. 30, 335–349 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Zhu S. et al. Expression and clinical implications of HAb18G/CD147 in hepatocellular carcinoma. Hepatology Research. 45, 97–106 (2015). [DOI] [PubMed] [Google Scholar]
  42. Li H. G. et al. Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol. 11, 1445–1451 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Tsai W. C. et al. Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters. World J Urol. 25, 73–80 (2007). [DOI] [PubMed] [Google Scholar]
  44. Hakuma N. et al. High Incidence of Extracellular Matrix Metalloproteinase Inducer Expression in Non-Small Cell Lung Cancers. Oncology. 72, 197–204 (2007). [DOI] [PubMed] [Google Scholar]
  45. Tsai W. C. et al. EMMPRIN and fascin overexpression associated with clinicopathologic parameters of pancreatobiliary adenocarcinoma in Chinese people. APMIS. 115, 929–938 (2007). [DOI] [PubMed] [Google Scholar]
  46. Wu W. et al. Prediction of prognosis in gallbladder carcinoma by CD147 and MMP-2 immunohistochemistry. Med Oncol. 26, 117–123 (2009). [DOI] [PubMed] [Google Scholar]
  47. Buergy D. et al. Prognostic Impact of Extracellular Matrix Metalloprotease Inducer: Immunohistochemical Analyses of Colorectal Tumors and Immunocytochemical Screening of Disseminated Tumor Cells in Bone Marrow From Patients With Gastrointestinal Cancer. Cancer. 115, 4667–4678 (2009). [DOI] [PubMed] [Google Scholar]
  48. Du Z. M. et al. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int.J. Cancer. 125, 1832–1841 (2009). [DOI] [PubMed] [Google Scholar]
  49. Han Z. D. et al. Expression and Clinical Significance of CD147 in Genitourinary Carcinomas. Journal of Surgical Research. 160, 260–267 (2010). [DOI] [PubMed] [Google Scholar]
  50. Sweeny L. et al. CD147 Expression in Advanced Cutaneous Squamous Cell Carcinoma. J Cutan Pathol. 39, 603–609 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Nakamura K., Kodama J., Hongo A. & Hiramatsu Y. Role of emmprin in endometrial cancer. BMC Cancer. 12, 191–201 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Sato M. et al. EMMPRIN Promotes Angiogenesis, Proliferation, Invasion and Resistance to Sunitinib in Renal Cell Carcinoma, and Its Level Predicts Patient Outcome. PLOS ONE. 8, e74313 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Tsai W. C. et al. EMMPRIN expression positively correlates with WHO grades of astrocytomas and meningiomas. J Neurooncol. 114, 281–290 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Yang Q. et al. Expression of COX-2, CD44v6 and CD147 and Relationship with Invasion and Lymph Node Metastasis in Hypopharyngeal Squamous Cell Carcinoma. PLOS ONE 8, e71048 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Zhong X. et al. Overexpressions of RACK1 and CD147 Associated with Poor Prognosis in Stage T1 Pulmonary Adenocarcinoma. Ann Surg Oncol. 20, 1044–1052 (2013). [DOI] [PubMed] [Google Scholar]
  56. Choi J. W., Kim Y., Lee J. H. & Kim Y. S. Prognostic Significance of Lactate/Proton Symporters MCT1, MCT4, and Their Chaperone CD147 Expressions in Urothelial Carcinoma of the Bladder. Urology. 84, 245.e9e–245. e15 (2014). [DOI] [PubMed] [Google Scholar]
  57. Huang X. Q. et al. Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma. Int J Clin Exp Pathol. 7, 1651–1666 (2014). [PMC free article] [PubMed] [Google Scholar]
  58. Pinheiro C. et al. Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization. Journal of Translational Medicine. 12, 118–128 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Kim Y., Choi J. W., Lee J. H. & Kim Y. S. Expression of lactate/H+ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma:immunohistochemical and The Cancer Genome Atlas data analyses. Human Pathology. 46, 104–112 (2015). [DOI] [PubMed] [Google Scholar]
  60. Liang Y. X. et al. CD147 and VEGF Expression in Advanced Renal Cell Carcinoma and Their Prognostic Value. Cancer Invest. 27, 788–93 (2009). [DOI] [PubMed] [Google Scholar]
  61. Yang H. & Chen B. CD147 in ovarian and other cancers. Int J Gynecol Cancer. 23, 2–8 (2013). [DOI] [PubMed] [Google Scholar]
  62. Fu J. et al. CD147 and VEGF co-expression predicts prognosis in patients with acute myeloid leukemia. pn J Clin Oncol. 40, 1046–52 (2010). [DOI] [PubMed] [Google Scholar]
  63. Zhou Q. et al. VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol. 20, 13–19 (2011). [DOI] [PubMed] [Google Scholar]
  64. Chen T. & Zhu J. Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. Med Oncol. 27, 1185–1191 (2010). [DOI] [PubMed] [Google Scholar]
  65. Gu J. et al. Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. Eur J Pediatr. 168, 705–710 (2009). [DOI] [PubMed] [Google Scholar]
  66. Zhang C., Tu Z., Du S., Wang Y. & Wang Q. Expression of matrix metalloproteinase 2 and extracellular matrix metalloproteinase inducer are unfavorable postoperative prognostic factors in intrahepatic cholangiocarcinoma. Pathol Oncol Res. 16, 47–53 (2010). [DOI] [PubMed] [Google Scholar]
  67. Kuang Y. H. et al. RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Cancer Letters. 276, 189–195 (2009). [DOI] [PubMed] [Google Scholar]
  68. Parmar M. K., Torri V. & Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Journal of the Statist Med. 17, 2815–2834 (1998). [DOI] [PubMed] [Google Scholar]
  69. Higgins J. P. & Thompson S. G. Quantifying heterogeneity in a meta-analysis. Stat Med. 15, 1539–1558 (2002). [DOI] [PubMed] [Google Scholar]
  70. Duval S. Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments (eds Rothstein H. R. et al.) 127–144 (John Wiley & Sons, 2005). [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep32804-s1.doc (21.5MB, doc)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES